



# Methods for detecting of cardiac troponin I biomarkers for myocardial infarction using biosensors: a narrative review of recent research

Qingzhuo Chen<sup>1</sup>, Wenxin Wu<sup>2</sup>, Ke Wang<sup>3,4</sup>, Zhijun Han<sup>5</sup>, Chengjian Yang<sup>1</sup>

<sup>1</sup>Department of Cardiology, The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi, China; <sup>2</sup>Department of Laboratory Medicine, Jiangnan University Medical Center, Wuxi, China; <sup>3</sup>National Key Laboratory of Radiopharmaceuticals, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, National Health Commission, Wuxi, China; <sup>4</sup>Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, China; <sup>5</sup>Department of Clinical Research Center, Jiangnan University Medical Center, Wuxi, China

**Contributions:** (I) Conception and design: C Yang, Z Han, K Wang; (II) Administrative support: C Yang; (III) Provision of study materials or patients: Z Han, C Yang; (IV) Collection and assembly of data: Q Chen; (V) Data analysis and interpretation: Q Chen, W Wu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Chengjian Yang, MD. Department of Cardiology, The Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, No. 68 Zhongshan Road, Wuxi 214001, China. Email: doctory2071@sina.com.

**Background and Objective:** In cardiovascular diseases (CVDs), acute myocardial infarction (AMI) is considered one of the leading causes of human death, and its diagnosis mainly relies on the detection of the cardiac biomarker troponin I. Traditional detection methods have certain limitations, which has prompted the development of methods with higher sensitivity and specificity. In recent years, biosensors, as an emerging technology, have been widely applied in the clinical medicine and biodetection fields. We retrieved and reviewed relevant articles published over the past 3 years and subsequently summarized the research progress of different types of biosensors in detecting cardiac troponin I and the challenges faced in achieving simple, specific, and portable point-of-care testing (POCT) technology for bedside rapid detection. The aim of this review is to serve as reference for the early diagnosis and treatment of CVDs.

**Methods:** This study searched for relevant literature published from 2019 to 2022 in the PubMed database of the National Center for Biotechnology Information (NCBI). The keywords used were as follows: “cardiac troponin I”, “biosensor”, “point-of-care testing”, “electrochemical detection”, and “surface-enhanced Raman spectroscopy”.

**Key Content and Findings:** The review found that biosensor technology has high specificity and sensitivity in the detection of cardiac troponin I and is simpler and more convenient than is traditional laboratory testing. Its vigorous development can facilitate the diagnosis of AMI earlier and faster.

**Conclusions:** This study reviewed the progress of cardiac troponin I detection based on biosensing strategies. We found that cardiac troponin I detection methods based on biosensing strategies have their own advantages and disadvantages in clinical applications, and their sensitivity has been constantly improved. In the future, the detection of cardiac troponin I using biosensing technology will be simpler, faster, more sensitive, and portable.

**Keywords:** Cardiac troponin I (cTn I); biosensor; point-of-care testing (POCT); electrochemical detection; surface-enhanced Raman spectroscopy (SERS)

Submitted Aug 11, 2023. Accepted for publication Sep 14, 2023. Published online Sep 25, 2023.

doi: 10.21037/jtd-23-1263

View this article at: <https://dx.doi.org/10.21037/jtd-23-1263>

## Introduction

Cardiovascular diseases (CVDs) constitute an increasingly serious epidemic with high morbidity and mortality rates worldwide. Acute myocardial infarction (AMI) is one of the leading causes of death related to CVDs, and thus the timely and accurate diagnosis of AMI is crucial (1,2).

Physicians mainly diagnose patients with AMI based on clinical manifestations, electrocardiography (ECG), and changes in cardiac biomarker levels (3). Among these strategies, the continuous measurement of cardiac biomarker troponin plays a key role. Troponin is composed of 3 regulatory proteins, including cardiac troponin C (cTn C), cardiac troponin I (cTn I), and cardiac troponin T (cTn T). cTn I, with its high specificity and sensitivity, has become the gold standard for diagnosing AMI (4). International guidelines recommend using high-sensitivity cardiac troponin (hs-cTn) detection and the 99th percentile upper limit as the threshold for diagnosing myocardial infarction (5).

Researchers have extensively explored methods for detecting troponin, including enzyme-linked immunosorbent assay (ELISA), chemiluminescence, fluorescence analysis, gold-labeled immunoassay, and immunoturbidimetry, each of which has a valuable role in detection. Over the past decade, many studies have combined biosensors, nanomaterials, and immunoassays to develop ultrasensitive sensing technologies, achieving higher sensitivity (6-9). Biosensors are an emerging molecular biotechnology with certain advantages, such as high analytical sensitivity, strong specificity, ease of use, and low cost. They are now widely applied in the clinical medicine and biodetection fields. This paper reviews the progress of cTn I detection based on biosensing strategies and discusses the challenges faced by portable point-of-care testing technology in achieving the early-as-possible diagnosis and treatment of CVDs. We present this article in accordance with the Narrative Review reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1263/rc>).

## Methods

This study was conducted in the digital library of Nanjing Medical University in Jiangsu, China. Ethical approval or permission was not required, as the study did not directly involve animal or human subjects. Relevant literature on the definitions, types, and applications of biosensors in

cardiac troponin I detection was collected. All data were obtained from the PubMed database of the National Center for Biotechnology Information (NCBI). For data collection, we used the following medical subject headings (MeSH) terms and their combinations in the title or abstract: “cardiac troponin I”, “biosensor”, “point-of-care testing”, “electrochemical detection”, and “surface-enhanced Raman spectroscopy”. *Table 1* outlines the details of the search strategy.

## Types of biosensors for detecting cardiac troponin I

Biosensors rely on biological molecules such as antibodies, aptamers, and enzymes as target recognition elements to convert the interaction between these elements and corresponding target molecules into quantifiable signals for detection by immobilizing them on transducers (10,11).

There are 2 main types of biological elements used to recognize cTn: antibodies and aptamers. Due to their high specificity and affinity, antibodies have become the mainstay of biological molecule recognition in practical applications (12). Aptamers, which are short single-stranded DNA or RNA molecules, are capable of binding to target molecules based on the diversity of single-stranded nucleic acid structures and spatial conformations. They also have advantages such as easy in vitro production, biocompatibility, convenient modification, and a broad range of potential targets (13,14).

Nanotechnology is an emerging, dynamic, multidisciplinary field. Nanomaterials possess unique mechanical, electrical, catalytic, thermal, magnetic, and imaging properties and come in various forms, such as nanoparticles, nanoflowers, nanofibers, and nanotubes. They have been used in cardiac troponin biosensor research to enhance biosensor performance (15).

Gold nanoparticles are the most commonly used nanoparticles, exhibiting surface plasmon resonance on the nanoscale. This prominent feature enables their wide application in chemical and biosensing (16). For example, Bai *et al.* developed citrate-capped trimetallic Au@Ag-Pt nanoparticles through seed growth and galvanic replacement reactions under convenient conditions. The bell-like structure endowed the Au@Ag-Pt nanoparticles with peroxidase-like activity while retaining plasmonic properties with strong colors in the visible range. This study successfully achieved the ultrasensitive colorimetric detection of human cTn I as low as 20 pg/mL (17). Khushai

**Table 1** The search strategy summary

Item	Specification
Date of search	October 1, 2022, to January 31, 2023
Databases and other sources searched	NCBI, PubMed
Search terms used	“cardiac troponin I”, “biosensor”, “point-of-care testing”, “electrochemical detection”, and “surface-enhanced Raman spectroscopy”
Time frame	March 1, 2019, to January 31, 2023
Inclusion criteria	Literature published in English from March 1, 2019, to January 31, 2023, was collected. The literature was mainly related to the medical field, especially cardiovascular diseases
Selection process	Chen Q, Wu W, and Han Z jointly collected and collated the data. The information was then classified and analyzed by Chen Q

NCBI, National Center of Biotechnology Information.

*et al.* developed a FET-based biosensing technique by connecting solid-state devices and biorecognition elements with porous carbon nitride modified by gold nanoparticles, with indium, gallium, and zinc oxide serving as a suitable semiconductor channel. The biosensor had a detection limit of 6.6 pg/mL and a dynamic range of  $10^{-10}$ – $10^6$  pg/mL (18).

MoS<sub>2</sub>, a 2D nanomaterial, is widely used due to its large surface area and numerous exposed active edges. Wang *et al.* established a sandwich-type ECL immunoassay for cTn I detection, in which molybdenum disulfide@cuprous oxide-silver nanoparticles (MoS<sub>2</sub>@Cu<sub>2</sub>O-Ag) immobilized cTn I as a capture antibody (Ab<sub>1</sub>), and Ce-doped zinc oxide@nitro-embedded graphene quantum dots (Ce:ZnO@NGQDs) loaded signal antibody (Ab<sub>2</sub>). The MoS<sub>2</sub>@Cu<sub>2</sub>O-Ag nanoparticles not only had good conductivity and biocompatibility but also a large specific surface area. Ce-doped zinc oxide acted as a c-reactant promoter, enabling the transformation of the Ce<sup>4+</sup> ↔ Ce<sup>3+</sup> reaction and accelerating electron exchange, thus achieving signal enhancement. Under optimal conditions, the sensor had a detection limit of 0.0029 pg/mL (19).

However, MoS<sub>2</sub> has low conductivity, and van der Waals forces between layers tend to cause agglomeration. Reduced graphene oxide has active edge centers and excellent electrical properties, which can effectively improve MoS<sub>2</sub>'s electrochemical activity and further amplify the signal. For example, Li *et al.* proposed a novel aptamer-based electrochemical sensor composed of silver nanoparticles, molybdenum disulfide, and graphene oxide. The combination of these three materials provided a synergistic effect for the stable immobilization of nucleic acid aptamers.

The optimized aptamer sensor had a linear range of 0.3–200 pg/mL and a detection limit of 0.27 pg/mL for cTn I detection (20).

In order to develop sensors for cTn I with high sensitivity and specificity, antibodies, aptamers and a variety of nanomaterials have been used in various sensors, including electrochemical, chemiluminescence, colorimetric, surface plasmon resonance, surface-enhanced Raman spectroscopy (SERS), and fluorescence biosensors (21).

### Electrochemical biosensors

Electrochemical biosensors have advantages, such as easy handling, portability, and good integration, and are easily self-assembled with antibodies and aptamers as recognition elements. Electrochemical biosensors can be divided into several types, including voltammetric, potentiometric, electrochemical impedance spectroscopy, electrochemical luminescence, and field-effect transistors signal sensors (21,22).

The working principle of voltammetric biosensors is to apply voltage to the working electrode as a signal input and then to detect the signal output by measuring the current (22). For example, Villalonga *et al.* constructed a novel amperometric aptasensor for specific detection of cTn I using a carboxyethylsilanetriol-modified graphene oxide as the sensing element, which can easily and highly load aminated DNA aptamers on the electrode surface, forming a sandwich structure with a novel aptamer-peroxidase conjugate as the signal element. The detection range of the sensor is  $1-10^6$  pg/mL, with a detection limit of 0.6 pg/mL. The authors also tested the sensor on voluntary donor

serum samples and compared it to a chemiluminescent procedure assay, achieving a low relative error of 9.2%. It was shown that the sensor is also highly reliable and accurate in the analysis of real samples (23).

The working principle of potentiometric biosensors is to record the potential accumulated on the working electrode. For example, Ni *et al.* reported a new 1-step potentiometric immunoassay. First, cTn I biomolecules were immobilized on the surface of gold nanoparticles (AuNPs) functionalized screen-printed graphite electrodes (SPGEs); then, rabbit anti-cTn I polyclonal antibodies were covalently coupled to di-dimethylmethylphenol dendrimers via a typical carbodiimide coupling method. As the target cTn I increased, the dendrimers were captured by the immunosensor decrease, resulting in a change in electrode potential. The potentiometric immunosensor has a good potential response to cTn I, with a linear detection range of  $1-10^5$  pg/mL and a detection limit of 7.3 pg/mL. Serum specimens from patients with cardio-cerebrovascular diseases were tested using this sensor and a commercial cTnI ELISA kit, respectively. The RSD of both was less than 12% (7).

Electrochemical impedance spectroscopy (EIS) is a highly sensitive technique that relies on the amount and conductivity of surface-adsorbed materials (24). Palanisamy *et al.* constructed a 3D immunosensor based on a metal-organic framework (MOF)-loaded nickel foam (NF). The biosensor was prepared by modifying the substrate with MOF material to achieve amine-functionalized electrodes, with a detection limit of 0.013 pg/mL and high specificity (8).

Electrochemiluminescence (ECL) detection of cTn I has certain advantages, such as high luminescence intensity, simple operation, low cost, and low background signal, and has become a new technology for clinical diagnosis. For example, Wang *et al.* constructed a solid-state ECL immunobiosensor based on a sandwich-type silica nanofilm, using a new electrochemiluminescence signal amplification strategy based on photonic crystal nanofilm light-scattering enhancement. A novel tightly packed monolayer silica film was fabricated as a solid-state electroluminescent electrode to achieve signal amplification. Under optimal conditions, the immunosensor had a detection limit of 0.0056 pg/mL for cTnI (25). Additionally, Du *et al.* established a label-free differential electrochemiluminescence immunosensor, which effectively eliminated cumulative errors, showing higher sensitivity, selectivity, and accuracy, with a detection limit of 0.00501 pg/mL and a detection range of  $0.01-10^3$  pg/mL (9).

Field-effect transistor (FET) biosensors are based on metal oxide field-effect transistors, with gate control

induced by the response of biomolecules to changes in surface charge. For example, Chang *et al.* developed a silicon nanowire (SiNW) FET (SiNW-FET) biosensor device using a top-down fabrication process compatible with metal oxide semiconductor (MOS) technology. After fabrication, the SiNW surface was modified with cTn I monoclonal antibody (Mab-cTn I) to covalently immobilize the cTn I antigen. The device had a minimum detection limit of 16 pg/mL and a detection range of 25–500 pg/mL (26).

In summary, electrochemical biosensors have high sensitivity, high specificity, good stability, wide linear range, and low detection limits. However, they also face a few challenges, such as a time-consuming fabrication processes and difficulties in clinical application. In the future, by combining these methods with new technologies, their performance in clinical testing can be further improved.

### Colorimetry

Colorimetry is a technique that uses color changes of indicators to determine the concentration of a target in a solution (27). Enzyme-linked immunosorbent assay (ELISA) is one of the traditional colorimetric immunoassays and uses enzyme-coupled antibodies to directly or indirectly catalyze color reactions for quantification. Commonly used enzymes include horseradish peroxidase (HRP), alkaline phosphatase (ALP), and  $\beta$ -galactosidase.

However, traditional ELISA methods have limited sensitivity, complex operations, and high costs, and thus efforts to improve this method have been made. For example, Wen *et al.* constructed a 3-dimensional nanoenzyme-catalyzed nanoreactor by confining MOF-818 nanoenzyme within the pores of mesoporous tungsten trioxide ( $p\text{-WO}_3$ ) for the selective colorimetric detection of cTn I, with a linear range of  $0.05-10^5$  pg/mL and a detection limit of 0.018 pg/mL. The spiked healthy human serum samples were tested by the proposed aptasensor. The assay results were in good agreement with commercial ELISA kits (28).

Zhang *et al.* proposed an electrochemical-colorimetric dual-mode imprinting sensing strategy. First, they constructed an aptamer-functionalized  $\text{Fe}^{3+}$ -polydopamine ( $\text{Apt@Fe}^{3+}$ -PDA) as a sacrificial beacon for the preparation of recognition-site magnetic molecularly imprinted polymers for cTn I. Once cTn I was captured, the beacon formed a sandwich-like complex through binding with the aptamer. Under acidic conditions,  $\text{Apt@Fe}^{3+}$ -PDA dissociated, releasing a large amount of  $\text{Fe}^{3+}$  ions, which

then converted to Prussian blue. Using this sensor, the limit of detection values of the electrochemical method and colorimetry were 3.2 and 7.4 pg/mL, respectively (29).

### *Chemiluminescence*

Chemiluminescence is a detection technique that relies on the generation of photons triggered by various redox or hydrolysis reactions from substrates and does not require incident excitation light, providing a higher signal-to-noise ratio and a broader dynamic range (30).

To improve detection sensitivity, signal enhancers can be used as electron transfer mediators, including substituted phenols, substituted boronic acids, indoxyl, N-alkyl phenothiazine, 4-dialkyl aminopyridine, Co(II), Co single-atom catalysts, and poly[(N-isopropylacrylamide)-co(methacrylic acid)] (21). For example, Zhao *et al.* reported a novel enhanced chemiluminescent immunoassay (CLIA) for the determination of cTn I, which fully utilized poly[(N-isopropyl acrylamide)-co-(methacrylic acid)] [P(NIPAM-co-MAA)] microspheres as a new potential signal enhancer, using magnetic fluorescent nanoparticles as an internal standard to improve the precision of the method. In this sandwich method, the antigen in the sample was captured by the antibody immobilized on the surface of the magnetic fluorescent beads and recognized by another antibody labeled with acridine ester (AE) on the P(NIPAM-co-MAA) microspheres. This method yielded a detection limit of 0.116 pg/mL, which is significantly higher than that of traditional chemiluminescent immunoassays (31).

Additionally, nanomaterials, such as gold, silica, and silver nanoparticles, can be used as catalysts or chemical carriers to enhance chemiluminescent signals. These particles have strong catalytic properties that can increase the specific surface area and electron density. For example, Han *et al.* reported the development of a highly sensitive chemiluminescent lateral-flow assay (LFA) involving gold nanoparticles coupled with aldehyde-activated HRP and antibody molecules (i.e., AuNP-(ald)HRP-Ab) as a new conjugation scheme for high-performance LFA testing, which achieved a detection limit of 5.6 pg/mL (32).

### *Fluorescence methods*

Fluorescence-based sensors use fluorescent dyes or nanostructured markers to capture molecules for efficient detection of cardiac biomarkers. It has the advantages of high sensitivity and a clinically relevant linear dynamic

range. Nevertheless, the quantum yield of fluorophores is low and the sensitivity of fluorescent sensors depends on the stability of light. Based on the mechanism of fluorescence signal transmission, fluorescence methods for cTn I analysis are mainly divided into 3 categories: coupling single fluorescent labels, coupling multiple fluorescent labels, and generating fluorescent labels through enzyme coupling (33). Single fluorescent labels refer to the analysis of fluorescent labels directly bound to detection antibodies or added to detection antibodies during binding events. Many studies have improved labeling and enzyme packaging and explored the use of multiple fluorescent labels that can be immobilized on highly porous substrates.

For example, Liu *et al.* constructed a direct, in situ, high-performance HRP-labeled fluorescent immunoassay platform based on the rapid in situ fluorescence reaction of polyethyleneimine (PEI) and p-phenylenediamine (PPD) analogs to generate fluorescent copolymer nanoparticles (FCNPs). By introducing different substituents in the PPD structure, the fluorescence wavelength of the FCNPs was adjusted. Using cTn I as the model antigen, a fluorescent enzyme-linked immunosorbent assay for cTn I was established. Compared to traditional ELISAs, this reaction platform not only reduces interference from background signals but also has good stability, adjustable wavelengths, and a high fluorescence quantum yield (34).

### *Digital immunoassay*

Digital immunoassays calculate single molecules bound to antibodies using plasma imaging technology, offering higher sensitivity and precision compared to traditional ELISAs. For example, Jing *et al.* reported a gradient-based digital immunoassay method by designing a multizone microfluidic channel with specific troponin capture antibodies. This method quantifies concentration gradients by optically imaging gold nanoparticles conjugated to detection antibodies bound to different test zones. Differential counting between zones eliminates the most common noise and nonspecific binding. This method requires only 1  $\mu$ L of plasma sample for troponin detection, with an analysis time of 30 minutes and a detection limit of 6.2 pg/mL. It features a simple design, high sensitivity, and real-time digital counting of recorded images (35).

### *Surface-enhanced Raman scattering (SERS)*

In recent years, SERS has been developed, which can

detect template molecules adsorbed on SERS substrates and produce significant Raman enhancement signals. The perfect SERS substrate has excellent detection performance, reaching extremely high detection limits, and possesses label-free recognition and rapid detection capabilities (36). Usually, noble metals (e.g., gold or silver nanoparticles) are used as Raman-active signals. Under appropriate laser wavelength excitation, the enhanced local electromagnetic field around noble metal nanoparticles is the main driving force for SERS (37). Tu *et al.* developed an aptamer-based SERS test strip for detecting cTn I, using silica, malachite green isothiocyanate (MGITC), and gold nanoparticles to provide strong and stable SERS signals at a 638-nm excitation wavelength. The lateral flow strip design was used to construct the paper fluidics strip. In the presence of cTn I, the aptamer/silica/MGITC/AuNPs, cTn I, and aptamer formed a sandwich binding on the test line. The SERS signal on the test line increased with increasing cTn I concentration, with a detection limit of 16 pg/mL (38). Lin *et al.* prepared coral-shaped silver-coated magnetic nanoparticles as substrates using aptamer-modified Fe<sub>3</sub>O<sub>4</sub>@PEI/Ag NC-Apt as a magnetic capture probe. This method combined the bicinchoninic acid assay method and SERS detection technology, successfully constructing an Apt-SERS detection platform. With cTn I as the detection target, the detection range was 1–10<sup>5</sup> pg/mL, and the lowest detection limit was 0.23 pg/mL (39). While SERS has obvious merits, it also has some drawbacks that cannot be ignored. Raman measurement can be performed in solution or statically on the surface of the substrate. When we chose the solution, due to the continuous movement of the plasmonic material, the reproducibility of the experiment can be low. If we select static operation, some steps in the analysis process can make the proposal more complex. Therefore, we still need to continuously improve in these aspects (40).

### Surface plasmon resonance (SPR)

SPR biosensors are label-free. It is capable of detecting cTn I in a simple and rapid manner. Despite significant progress in development, the sensitivity of the SPR biosensor assay needs to be improved to reach values sufficient for clinical diagnosis. SPR biosensors mainly include long-range surface plasmon polaritons (LRSPPs), gold nanoparticle SPR, SPR fluorescence spectroscopy, surface plasmon-enhanced scattering, and ultrasensitive plasmonic biosensors. For example, Hua *et al.* reported a fiber-based SPR biosensor

with DNA aptamers specific to cTn I. By optimizing its surface concentration, the sensor had a detection limit of 0.0575 pg/mL for cTn I (41).

We have summarized the characteristics of various biosensing strategies for detecting cTn I in Table 2, which includes performance parameters.

### Clinical translation

Currently, cTn detection is mainly laboratory-based, and there is an urgent need to shorten turnaround times for the clinical diagnosis of AMI. Point-of-care testing (POCT) is a specific form of diagnostic testing that can be performed without accompanying infrastructure or complex instruments (42). POCT devices, small benchtop instruments, and handheld devices have become emerging development targets for biosensors in bedside cardiac biomarker testing. Some recent bedside cTn I testings include gate-controlled FET biosensors, colorimetric immunosensors, and paper-based lateral-flow immunoassays (LFIA).

Sinha *et al.* designed an integrated microfluidic chip with immobilized highly specific aptamer probes and an FET sensor array for detecting 4 cardiovascular protein biomarkers (C-reactive protein, N-terminal pro-B-type natriuretic peptide, cTn I, and fibrinogen). This low-power, FET-based system required no sample preparation and enabled fully automatic detection of clinical samples (~4 µL) within 5 minutes through microfluidic and portable controllers. It had an area of only 4.0 cm × 3.3 cm and was proved suitable for large-scale production, with a detection range of 1–10<sup>4</sup> pg/mL and a detection limit of 0.394 pg/mL (43).

Fluorescent or colorimetric immunosensors based on dry chemistry have been widely used in bedside testing. For example, Zhan *et al.* designed a dry chemistry- and lateral-flow analysis-based, closed bipolar electrode ECL (CBP-ECL) immunosensor. The sensor, consisting of a fibrous material chip and a shell, could be easily manufactured through screen printing and 3D printing. Ru(II)-L-cysteine composite materials were used as self-enhanced ECL probes. The ECL signals generated by antibody-functionalized Ru(II)-L-Cys allowed for the sensitive quantification of cTn I. The immunosensor had a wide linear range (1–10<sup>5</sup> pg/mL) and acceptable sensitivity (0.4416 pg/mL). Furthermore, testing of cTnI clinical serum/plasma samples has shown a strong correlation with high-end laboratory equipment and can be used in real-world situations (44).

**Table 2** Comparison of biosensing-based strategies for detecting cardiac troponin I

Type	Materials	Detection limit (pg/mL)	Detection range (pg/mL)	Reference
Electrochemical biosensor				
Voltammetric type	Apt-CES-GO/SPE	0.6	1–10 <sup>6</sup>	(23)
Potentiometric type	Ab-DE-COOH/cTn I/AuNP/SPGE	7.3	1–10 <sup>5</sup>	(7)
EIS	Ab-NH <sub>2</sub> -MIL-88B(Fe <sub>2</sub> Co)-MOF/NF	0.013	10 <sup>-4</sup> –10 <sup>5</sup>	(8)
ECL method	BSA/Ab-AgNPs/CdS@MOF-5/PDDA/FTO	0.005	0.01–10 <sup>3</sup>	(9)
FET	APTES/glutaraldehyde-modified SiNW-FET	16	25–500	(26)
Colorimetric method	GP/MOF-818@p-WO <sub>3</sub> /c-DNA/apt-glu aptasensor	0.018	0.05–10 <sup>5</sup>	(28)
Chemiluminescence method	AuNP-(ald)HRP-Ab conjugate	5.6	1–10 <sup>4</sup>	(32)
Fluorescence method	PEI-PPD FCNPs	190	5×10 <sup>3</sup> –1.8×10 <sup>5</sup>	(34)
Digital immunoassay method	AuNPs/microfluidic chip	6.2		(35)
SERS	Fe <sub>3</sub> O <sub>4</sub> @PEI/Ag NC-Apt	0.23	1–10 <sup>5</sup>	(39)
SPR	chromium film/gold film/fiber	0.0575		(41)

EIS, electrochemical impedance spectroscopy; ECL, electrochemiluminescence; FET, field-effect transistor; SERS, surface-enhanced Raman scattering; SPR, surface plasmon resonance.

**Table 3** Comparison of POCT equipment for detecting cardiac troponin I

Type	Materials	Detection time (min)	Detection limit (pg/mL)	Detection range (pg/mL)	Reference
Field effect transistor	HEMT-microfluidic chip/Apt	5	0.394	1–10 <sup>4</sup>	(43)
Colorimetric method	Ru(II)-L-Cys/GQDs-AuNPs/Ab/CBP-ECL	7	0.4416	1–10 <sup>5</sup>	(44)
Paper-based lateral-flow analysis	AuNP-polyHRP-Ab Conjugate	20	0.84	10–48,310	(45)

POCT, point-of-care testing.

Paper-based lateral flow assays (LFAs) is one of the most widely applied medical device detection biosensing platforms. For example, Han *et al.* developed a highly sensitive, automated LFA biosensing platform that incorporated gold nanoparticles into a polymer network of HRP conjugated with antibodies, enhancing enzyme coupling. This overcame the limitations of traditional colloidal gold-labeling methods, such as low sensitivity and limited quantification capabilities. The platform integrated a time-programmable amplification section based on water-soluble polymers for automated immunoanalysis and sequential reactions in signal amplification. The simple operation steps requiring no user intervention. It could automatically detect human cTn I in serum samples within 20 minutes, with a detection limit of 0.84 pg/mL. In addition, it costs only \$0.66 per test. In summary, it has

been proved to be practical and cost-effective (45).

Table 3 compares the performance parameters of the aforementioned POCT devices. These three POCT devices use different integration methods and can be detected automatically. The detection time ranged from a few minutes to tens of minutes. Each has its own advantages in terms of instrument volume and detection cost. In addition, we note that in (43) the authors used an integrated microfluidic chip. In recent years, microfluidics has gained much attention due to its functional characteristics such as high efficiency. Microfluidic systems, such as microfluidic chips, which are small in size, consume less samples, and are portable, are an important direction for the development of new-generation POCT instruments (46). By combining microfluidic systems with different types of biosensors, we are able to overcome some of the complexity problems of

fluid handling (47).

While POCT devices have many advantages, they also have certain limitations that need further improvement, such as enhanced stability, the ability to detect different biomarkers simultaneously, and a greater degree of automated signal acquisition and analysis. Manufacturing microfluidic systems that are safe and economical, more easily scalable and can be effectively cleaned and reused, and combining them with sensors are also not negligible. In the future, POCT should be developed to be highly integrated, miniaturized, cost-effective, and easy-to-operate detection systems.

## Conclusions

This paper reviews the current state of research on cTn I biosensor technology, summarizing the characteristics of biosensors based on electrochemical, colorimetric, fluorescent, chemiluminescent, and SERS techniques. Most biosensors use immunoassay technology for detection, with antibodies as the biological components. In recent years, aptamer sensors have emerged as a viable alternative to immunosensors, offering advantages such as ease of chemical modification, flexibility, and high affinity. Sensing strategies based on nanoparticles and nanomaterials can amplify detection signals, further improving the sensitivity and performance of sensors. The goal is to develop portable, stable, sensitive, and rapid analysis detection devices. To meet these needs, future development directions may include developing more novel biorecognition elements (such as artificial receptors) and not simply traditional antibodies; developing composite biosensors for multiplex detection, allowing for the timely and cost-effective simultaneous measurement of multiple analytes; and developing in vivo sensors to continuously and track changes in biomarker concentrations real-time. In summary, cTn I detection methods based on biosensors will become increasingly simple, sensitive, and stable, enabling the early diagnosis and treatment of AMI.

## Acknowledgments

*Funding:* The study was supported by the Foundation of Wuxi Municipal Health Commission, China.

## Footnote

*Reporting Checklist:* The authors have completed the

Narrative Review reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1263/rc>

*Peer Review File:* Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1263/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1263/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Zhao D. Epidemiological Features of Cardiovascular Disease in Asia. *JACC Asia* 2021;1:1-13.
2. Hartikainen TS, Sörensen NA, Haller PM, et al. Clinical application of the 4th Universal Definition of Myocardial Infarction. *Eur Heart J* 2020;41:2209-16.
3. Nagele P. A Simplified Proposal to Redefine Acute Myocardial Infarction Versus Acute Myocardial Injury. *Circulation* 2020;141:1431-3.
4. Canty JM Jr. Myocardial injury, troponin release, and cardiomyocyte death in brief ischemia, failure, and ventricular remodeling. *Am J Physiol Heart Circ Physiol* 2022;323:H1-H15.
5. Chapman AR, Adamson PD, Shah ASV, et al. High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. *Circulation* 2020;141:161-71.
6. Campu A, Muresan I, Craciun AM, et al. Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges. *Int J Mol Sci* 2022;23:7728.
7. Ni E, Fang Y, Ma F, et al. A one-step potentiometric immunoassay for plasma cardiac troponin I using an



- antibody-functionalized bis-MPA-COOH dendrimer as a competitor with improved sensitivity. *Anal Methods* 2020;12:2914-21.
8. Palanisamy S, Senthil Raja D, Subramani B, et al. Label-Free Bimetallic In Situ-Grown 3D Nickel-Foam-Supported NH<sub>2</sub>-MIL-88B(Fe<sub>2</sub>Co)-MOF-based Impedimetric Immunosensor for the Detection of Cardiac Troponin I. *ACS Appl Mater Interfaces* 2020;12:32468-76.
  9. Du D, Shu J, Guo M, et al. Potential-Resolved Differential Electrochemiluminescence Immunosensor for Cardiac Troponin I Based on MOF-5-Wrapped CdS Quantum Dot Nanoluminophores. *Anal Chem* 2020;92:14113-21.
  10. Tao X, Wang X, Liu B, Liu J. Conjugation of antibodies and aptamers on nanozymes for developing biosensors. *Biosens Bioelectron* 2020;168:112537.
  11. Reich P, Preuß JA, Bahner N, et al. Impedimetric Aptamer-Based Biosensors: Principles and Techniques. *Adv Biochem Eng Biotechnol* 2020;174:17-41.
  12. Ma H, Cassidy A, O'Kennedy R. The role of antibody-based troponin detection in cardiovascular disease: A critical assessment. *J Immunol Methods* 2021;497:113108.
  13. Hosseinzadeh L, Mazloum-Ardakani M. Advances in aptasensor technology. *Adv Clin Chem* 2020;99:237-79.
  14. Komarova N, Panova O, Titov A, et al. Aptamers Targeting Cardiac Biomarkers as an Analytical Tool for the Diagnostics of Cardiovascular Diseases: A Review. *Biomedicines* 2022;10:1085.
  15. Ramya M, Senthil Kumar P, Rangasamy G, et al. A recent advancement on the applications of nanomaterials in electrochemical sensors and biosensors. *Chemosphere* 2022;308:136416.
  16. Bezuneh TT, Fereja TH, Kittle SA, et al. Gold nanoparticle-based signal amplified electrochemiluminescence for biosensing applications. *Talanta* 2022;248:123611.
  17. Bai T, Wang L, Wang M, et al. Strategic synthesis of trimetallic Au@Ag-Pt nanorattles for ultrasensitive colorimetric detection in lateral flow immunoassay. *Biosens Bioelectron* 2022;208:114218.
  18. Khushaim W, Vijjapu MT, Yuvaraja S, et al. Graphitic Carbon Nitride and IGZO Bio-FET for Rapid Diagnosis of Myocardial Infarction. *Biosensors (Basel)* 2022;12:836.
  19. Wang B, Wang C, Li Y, et al. Electrochemiluminescence biosensor for cardiac troponin I with signal amplification based on a MoS<sub>2</sub>@Cu<sub>2</sub>O-Ag-modified electrode and Ce:ZnO-NGQDs. *Analyst* 2022;147:4768-76.
  20. Li J, Zhang S, Zhang L, et al. A Novel Graphene-Based Nanomaterial Modified Electrochemical Sensor for the Detection of Cardiac Troponin I. *Front Chem* 2021;9:680593.
  21. Du X, Su X, Zhang W, et al. Progress, Opportunities, and Challenges of Troponin Analysis in the Early Diagnosis of Cardiovascular Diseases. *Anal Chem* 2022;94:442-63.
  22. Singh A, Sharma A, Ahmed A, et al. Recent Advances in Electrochemical Biosensors: Applications, Challenges, and Future Scope. *Biosensors (Basel)* 2021;11:336.
  23. Villalonga A, Estabiel I, Pérez-Calabuig AM, Mayol B, Parrado C, Villalonga R. Amperometric aptasensor with sandwich-type architecture for troponin I based on carboxyethylsilanetriol-modified graphene oxide coated electrodes. *Biosens Bioelectron* 2021;183:113203.
  24. Strong ME, Richards JR, Torres M, et al. Faradaic electrochemical impedance spectroscopy for enhanced analyte detection in diagnostics. *Biosens Bioelectron* 2021;177:112949.
  25. Wang S, Li C, Saqib M, et al. Quasi-Photonic Crystal Light-Scattering Signal Amplification of SiO<sub>2</sub>-Nanomembrane for Ultrasensitive Electrochemiluminescence Detection of Cardiac Troponin I. *Anal Chem* 2020;92:845-52.
  26. Chang SM, Palanisamy S, Wu TH, et al. Utilization of silicon nanowire field-effect transistors for the detection of a cardiac biomarker, cardiac troponin I and their applications involving animal models. *Sci Rep* 2020;10:22027.
  27. Zhu D, Liu B, Wei G. Two-Dimensional Material-Based Colorimetric Biosensors: A Review. *Biosensors (Basel)* 2021;11:259.
  28. Wen R, Zhou C, Tian J, et al. Confined catalysis of MOF-818 nanozyme and colorimetric aptasensing for cardiac troponin I. *Talanta* 2023;252:123830.
  29. Zhang G, Zhang L, Yu Y, et al. Dual-mode of electrochemical-colorimetric imprinted sensing strategy based on self-sacrifice beacon for diversified determination of cardiac troponin I in serum. *Biosens Bioelectron* 2020;167:112502..
  30. Tzani MA, Gioftsidou DK, Kallitsakis MG, et al. Direct and Indirect Chemiluminescence: Reactions, Mechanisms and Challenges. *Molecules* 2021;26:7664.
  31. Zhao H, Lin Q, Huang L, et al. Ultrasensitive chemiluminescence immunoassay with enhanced precision for the detection of cTnI amplified by acridinium ester-loaded microspheres and internally calibrated by magnetic fluorescent nanoparticles. *Nanoscale* 2021;13:3275-84.
  32. Han GR, Kim MG. Highly Sensitive Chemiluminescence-Based Lateral Flow Immunoassay for Cardiac Troponin I

- Detection in Human Serum. *Sensors (Basel)* 2020;20:2593.
33. Radha R, Shahzadi SK, Al-Sayah MH. Fluorescent Immunoassays for Detection and Quantification of Cardiac Troponin I: A Short Review. *Molecules* 2021;26:4812.
  34. Liu J, Ruan G, Ma W, et al. Horseradish peroxidase-triggered direct in situ fluorescent immunoassay platform for sensing cardiac troponin I and SARS-CoV-2 nucleocapsid protein in serum. *Biosens Bioelectron* 2022;198:113823.
  35. Jing W, Wang Y, Chen C, et al. Gradient-Based Rapid Digital Immunoassay for High-Sensitivity Cardiac Troponin T (hs-cTnT) Detection in 1  $\mu$ L Plasma. *ACS Sens* 2021;6:399-407.
  36. Saviñon-Flores AI, Saviñon-Flores F, Trejo G, et al. A review of cardiac troponin I detection by surface enhanced Raman spectroscopy: Under the spotlight of point-of-care testing. *Front Chem* 2022;10:1017305.
  37. Koetz J. The Effect of Surface Modification of Gold Nanotriangles for Surface-Enhanced Raman Scattering Performance. *Nanomaterials (Basel)* 2020;10:2187.
  38. Tu D, Holderby A, Coté GL. Aptamer-based surface-enhanced resonance Raman scattering assay on a paper fluidic platform for detection of cardiac troponin I. *J Biomed Opt* 2020;25:097001.
  39. Lin C, Li L, Feng J, et al. A novel Apt-SERS platform for the determination of cardiac troponin I based on coral-like silver-modified magnetic substrate and BCA method. *Anal Chim Acta* 2022;1225:340253.
  40. Feng S, Yan M, Xue Y, et al. Electrochemical Immunosensor for Cardiac Troponin I Detection Based on Covalent Organic Framework and Enzyme-Catalyzed Signal Amplification. *Anal Chem* 2021;93:13572-9.
  41. Hua Y, Wang R, Li D. A Fiber-Based SPR Aptasensor for the In Vitro Detection of Inflammation Biomarkers. *Micromachines (Basel)* 2022;13:1036.
  42. Collinson P. Cardiac biomarker measurement by point of care testing - Development, rationale, current state and future developments. *Clin Chim Acta* 2020;508:234-9.
  43. Sinha A, Tai TY, Li KH, et al. An integrated microfluidic system with field-effect-transistor sensor arrays for detecting multiple cardiovascular biomarkers from clinical samples. *Biosens Bioelectron* 2019;129:155-63.
  44. Zhan T, Su Y, Lai W, et al. A dry chemistry-based ultrasensitive electrochemiluminescence immunosensor for sample-to-answer detection of Cardiac Troponin I. *Biosens Bioelectron* 2022;214:114494.
  45. Han GR, Ki H, Kim MG. Automated, Universal, and Mass-Produced Paper-Based Lateral Flow Biosensing Platform for High-Performance Point-of-Care Testing. *ACS Appl Mater Interfaces* 2020;12:1885-94.
  46. Feng J, Li N, Du Y, et al. Ultrasensitive Double-Channel Microfluidic Biosensor-Based Cathodic Photoelectrochemical Analysis via Signal Amplification of SOD-Au@PANI for Cardiac Troponin I Detection. *Anal Chem* 2021;93:14196-203.
  47. Sitkov N, Zimina T, Kolobov A, et al. Study of the Fabrication Technology of Hybrid Microfluidic Biochips for Label-Free Detection of Proteins. *Micromachines (Basel)* 2021;13:20.

**Cite this article as:** Chen Q, Wu W, Wang K, Han Z, Yang C. Methods for detecting of cardiac troponin I biomarkers for myocardial infarction using biosensors: a narrative review of recent research. *J Thorac Dis* 2023;15(9):5112-5121. doi: 10.21037/jtd-23-1263